Alan Sanders, MD
Family Medicine · Blairsville, GANPI 1063478691
Payments from drug & device makers
Across 405 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Amgen$722
- Novo Nordisk$650
- Bayer$543
- AstraZeneca$493
- Lilly USA, LLC$486
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,801100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 57 | $1,079 |
| Amgen | 42 | $722 |
| Novo Nordisk | 43 | $650 |
| Bayer | 32 | $543 |
| AstraZeneca | 31 | $493 |
| Lilly USA, LLC | 33 | $486 |
| Sanofi-aventis U.S. LLC | 26 | $403 |
| Pfizer | 22 | $342 |
| GSK | 21 | $333 |
| AbbVie | 14 | $271 |
| Corcept Therapeutics | 12 | $232 |
| Novartis | 12 | $207 |
| Eisai Inc. | 8 | $174 |
| Johnson & Johnson | 9 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $106 |
| Merck | 7 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Amarin Pharma, Inc. | 5 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Edwards Lifesciences | 1 | $38 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Verona Pharma, Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Abbott | 1 | $23 |
| Shire North American Group Inc | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Athena Bioscience, LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$6,821 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 289 | $337,160 |
| EliquisApixaban | 284 | $197,413 |
| OzempicSemaglutide | 95 | $133,405 |
| KerendiaFinerenone | 102 | $106,532 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $101,626 |
| MounjaroTirzepatide | 78 | $96,315 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 76 | $70,587 |
| TrulicityDulaglutide | 39 | $68,858 |
| NuplazidPimavanserin Tartrate | 21 | $52,197 |
| EntrestoSacubitril/Valsartan | 68 | $32,379 |
| XareltoRivaroxaban | 45 | $30,341 |
| FarxigaDapagliflozin Propanediol | 37 | $25,862 |
| JanuviaSitagliptin Phosphate | 24 | $25,726 |
| Repatha SureclickEvolocumab | 21 | $21,940 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $19,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $1,079 | $346,077307 claims |
| PfizerEliquis | $342 | $197,413284 claims |
| Lilly USA, LLCMounjaro, Trulicity | $486 | $165,173117 claims |
| Novo NordiskOzempic | $650 | $133,40595 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $333 | $120,634169 claims |
| BayerKerendia | $543 | $106,532102 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $403 | $74,618123 claims |
| NovartisEntresto | $207 | $32,37968 claims |
| Johnson & JohnsonXarelto | $129 | $30,34145 claims |
| AstraZenecaFarxiga | $493 | $25,86237 claims |
| MerckJanuvia | $94 | $25,72624 claims |
| AbbVieVraylar, Synthroid | $271 | $23,31772 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Blairsville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.